Small cell lung cancer

Cancer Control

Volumn 8, Issue 6 SUPPL., 2001, Pages 32-43

  Johnson, B E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; NAVELBINE; NITROSOUREA DERIVATIVE; PACLITAXEL; TAXANE DERIVATIVE; TENIPOSIDE; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMOSENSITIVITY; CIGARETTE SMOKING; CLINICAL FEATURE; CONFERENCE PAPER; HUMAN; LUNG SMALL CELL CANCER; PATHOGENESIS; PROGNOSIS; ADJUVANT THERAPY; AGE; LUNG TUMOR; PATHOLOGY; PRACTICE GUIDELINE; RISK FACTOR; SALVAGE THERAPY; SMALL CELL CARCINOMA; TREATMENT OUTCOME;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; HUMAN; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0035191955     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (77)

1. Cancer statistics, 2000
2. Therapy of small cell lung cancer: A perspective on two decades of clinical research
3. Extrapulmonary small-cell carcinoma. A review of the literature with emphasis on therapy and outcome
4. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies
5. Antigens of lung cancer: Results of the second international workshop on lung cancer antigens
6. CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides
7. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer
8. Respiratory tract and head and neck cancer
9. Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer
10. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression
11. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
12. The FHIT gene 3p14.2 is abnormal in lung cancer
13. Increased expression of N-myc in human small cell lung cancer biopsies predicts lack of response to chemotherapy and poor prognosis
14. Heterogenous amplification of myc family oncogenes in small cell lung carcinoma
15. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens
16. Long-term disease-free survival in small-cell carcinoma of the lung: A study of clinical determinants
17. A meta-analysis of thoracic radiotherapy for small-cell lung cancer
18. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis
19. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: A randomized trial of the Bristol Lung Cancer Study Group
20. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: A randomized trial of the North Central Cancer Treatment Group
21. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial
22. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B
23. VP-16 and cisplatin as first-line therapy for small-cell lung cancer
24. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer
25. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study
26. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer
27. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
28. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
29. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
30. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer
31. Potential for long-term survival in extensive stage small-cell lung cancer (ESCLC) with CODE chemotherapy and radiotherapy
32. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: A phase III randomized study conducted by the European Lung Cancer Working Party
33. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: A Cancer Research Campaign trial
34. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer
35. A randomized study of CODE plus thoracic irradiation versus alternating CAV/EP for extensive stage small-cell lung cancer (ESCLC)
36. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients
37. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council Multicenter Randomized Trial
38. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French Federation of Cancer Institutes multicenter phase III randomized study
39. Enhancement of fractionated radiation therapy by an experimental concentrated perflubron emulsion (Oxygent) in the Lewis lung carcinoma
40. Intensive chemotherapy of small cell bronchogenic carcinoma
41. High-dose cyclophosphamide in the induction therapy of small cell lung cancer: Minor improvements in rate of remission and survival
42. Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy
43. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer
44. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
45. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
46. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung
47. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer
48. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
49. Dose intensive therapy in lung cancer
50. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study
51. Intensive combined modality therapy for limited-stage small-cell lung cancer
52. Dose-intensive therapy for limited-stage small-cell lung cancer: Long-term outcome
53. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial
54. Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy
55. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer
56. New combination of the old drugs for elderly patients with small-cell lung cancer: A phase II study of the PAVE regimen
57. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer
58. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer
59. Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: The case for studies in previously treated patients
60. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: An Eastern Cooperative Oncology Group randomized study
61. Long survival in 15 patients with small cell lung cancer (SCLC) immunized with BEC2 plus BCG after initial therapy: An update
62. Immunotoxin therapy of small-cell lung cancer: A phase I study of N901-blocked ricin
63. Phase I study of an antigastrin releasing peptide (GRP) monoclonal antibody in patients with lung cancer
64. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung
65. Competing events determining relapse-free survival in limited small-cell lung carcinoma
66. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer
67. A preliminary report: Concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer
68. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A Southwest Oncology Group Study
69. Daily (qd) v twice-daily (bid) thoracic irradiation (TI) with concurrent cisplatin-etoposide (PE) for limited small cell lung cancer (LSCLC): Preliminary results on 352 randomized eligible patients
70. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer
71. Final results of a phase III study of concurrent versus seqential thoracic radiotherapy (TRT) in combination with cisplatin and etoposide for limited-stage small cell lung cancer (LD-SCLC: The Japan Clinical Oncology Group (JCOG) study
72. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
73. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
74. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
75. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy
76. Interleukin-2 activity in patients with extensive small-cell lung cancer: A phase II trial of Cancer and Leukemia Group B
77. Extensive-disease small-cell lung cancer: The thrill of victory; the agony of defeat